Blood
01 Jan 2013
Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
Randomized subjects will receive study drug, either thalidomide plus high-dose dexamethasone or placebo identical in appearance to thalidomide plus high-dose dexamethasone, in 4-week cycles. Subjects will remain on study drug until they experience disease progression or until the subject discontinues for any other reason. Subjects will have visits every cycle…
Cancer
01 Jan 2013
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.PURPOSE: Phase I trial to study the effectiveness of bortezomib in treating patients who have…
Research and Trials
01 Jan 2013
Renal Allograft Recipients Study
To determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function. Official Title A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients. Conditions – Renal Allograft Recipients Study Type Interventional Study…
Cancer
01 Jan 2013
Study of ONTAK in patients with B-Cell Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL) Official Title A Multicenter, Phase II Study of ONTAK (Denileukin Diftitox) in Patients with Previously-Treated Chronic Lymphocytic Leukemia Conditions – Leukemia, Lymphocytic, Chronic Study Type Interventional…
Cancer
01 Jan 2013
Assessing Quality of Life of Patients With Prostate Cancer
RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate and long-term effects of the treatment on these patients. Official Title Study of the EORTC QLQ-C30 and Prostate Cancer-Specific QLQ-PR25 Questionnaires to Assess Quality of Life of Patients With Stage I-IV Prostate Cancer…
Cancer
01 Jan 2013
Prostatectomy Compared With Watchful Waiting in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Watchful waiting until symptoms appear may be effective in patients with prostate cancer. It is not yet known if watchful waiting is more effective than prostatectomy for early prostate cancer. Official Title NCI HIGH PRIORITY CLINICAL TRIAL — Phase III Randomized Study of Prostatectomy Versus Expectant Management With Palliative…
Mental Health
01 Jan 2013
Therapeutic Processes and Treatment Outcome in Adolescents with Anxiety Disorders
The purpose of this study is to examine the relationship between different aspects of cognitive behavior therapy (CBT) and treatment outcome. Official Title Process as a Predictor of Outcomes in CBT for Youth Conditions – Anxiety Disorders Study Type Interventional Study Design Treatment, Non-Randomized, Open Label, Active Control, Single…
Cancer
01 Jan 2013
XELOX versus fluorouracil/leucovorin as therapy for surgery in association with colon carcinoma
The primary purpose of the study is to show that the combination of capecitabine plus oxaliplatin (XELOX) is better than the combination of fluorouracil/leucovorin (5-FU/LV) in terms of time to cancer relapse or death in patients who have had surgery for colon cancer (Dukes stage C) and have not received…
Infections
01 Jan 2013
Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis.
The purposes of this study are to determine: 1. Whether drotrecogin alfa (activated) helps children with severe sepsis survive their condition more often or recover faster than children who do not receive drotrecogin alfa (activated). 2. Whether drotrecogin alfa (activated) minimizes long term disabilities associated with severe sepsis. 3.
